Mediark, a South Korean medical IT startup, has raised approximately USD 2.2 million(KRW 3 billion) in a pre-Series A funding round led by JB Investment. The investment will fuel Mediark’s accelerated expansion into domestic and international markets.

Mediark’s flagship product, the AI-powered pre-consultation app Simtomi, enables users to input symptoms in their native language, generating a concise symptom summary for healthcare providers. The app has gained significant traction, earning an Excellence Award at the 2024 Best Practices Competition for Supporting Foreign Residents, hosted by South Korea’s Ministry of the Interior and Safety.

Currently supporting over 13 languages, Simtomi facilitated more than 8,000 medical consultations for foreign patients in its first year. User surveys reflect strong approval, with a 95% intent to reuse and an 84.4-point satisfaction score.

Building on this success, Mediark launched Simtomi-Care, a service that converts patient data into medical terminology and automatically relays it to healthcare providers, streamlining consultations. The service has reduced average consultation times by over 60%, driving rapid B2B revenue growth among domestic and international healthcare institutions and local governments. Interest from major hospitals and corporations is also on the rise.

Mediark is intensifying its global outreach. Following a 2024 partnership with South Africa’s AGE Group PTY LTD, the company has begun exporting its services, diversifying its international distribution channels.

“Mediark has consistently demonstrated strong growth potential and is poised to become a leader in the medical AI sector,” said Hari Yoon, Managing Director at JB Investment. “This investment will accelerate Mediark’s expansion in the global market.”

Mediark CEO Chan-hyung Lee stated, “While our focus has been on multilingual medical coordination and consultation efficiency for domestic institutions, we now aim to scale our platform to overseas hospitals and corporations. This funding will solidify our position as a global leader in medical IT.”

Mediark, a resident company of Seoul Bio Hub, a biotech and medical startup innovation platform, continues to benefit from robust ecosystem support.